Melatonin attenuates impairments of structural hippocampal neuroplasticity in OXYS rats during active progression of Alzheimer's disease-like pathology

Journal of Pineal Research

Volumn 59, Issue 2, 2015, Pages 163-177

  Stefanova, Natalia A ^a   Maksimova, Kseniya Y ^b   Kiseleva, Elena ^a   Rudnitskaya, Ekaterina A ^a   Muraleva, Natalia A ^a   Kolosova, Nataliya G ^a,c,d  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^c NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^d Institute of Mitoengineering   (Russian Federation)

Author keywords

Alzheimer's disease; melatonin; neurodegeneration; neuroinflammation; neuroplasticity; OXYS rats; synapse

Indexed keywords

MELATONIN; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPSIN I; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; GLIA CELL; HIPPOCAMPUS; MALE; NERVE CELL; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; OXYS RAT; POSTSYNAPTIC DENSITY; RAT; SYNAPSE; ANIMAL; DISEASE MODEL; METABOLISM; PATHOLOGY; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; MELATONIN; NEURONAL PLASTICITY; POST-SYNAPTIC DENSITY; RATS; RATS, WISTAR;

EID: 84938416838     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12248     Document Type: Article

References (77)

1. Selkoe DJ,. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
2. Hardy J, Selkoe DJ,. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
3. Lacor PN, Buniel MC, Chang L, et al., Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004; 24: 10191-10200.
4. Choi SH, Bosetti F,. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging 2009; 1: 234-244.
5. Massaad CA, Pautler RG, Klann E,. Mitochondrial superoxide: a key player in Alzheimer's disease. Aging 2009; 1: 758-761.
6. Mu YL, Gage FH,. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener 2011; 6: 85.
7. Moreira PI, Honda K, Liu Q, et al., Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. Curr Alzheimer Res 2005; 2: 403-408.
8. Chaturvedi RK, Flint Beal M,. Mitochondrial diseases of the brain. Free Radic Biol Med 2013; 63: 1-29.
9. Krstic D, Knuesel I,. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013; 9: 25-34.
10. Drachman DA,. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement 2014; 3: 372-380.
11. Shinohara M, Fujioka S, Murray ME, et al., Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain 2014; 137: 1533-1549.
12. Spires-Jones TL, Hyman BT,. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 2014; 82: 756-771.
13. Liu L, Drouet V, Wu JW, et al., Trans-synaptic spread of tau pathology in vivo. PLoS ONE 2012; 7: e31302.
14. Rosales-Corral SA, Acuna-Castroviejo D, Coto-Montes A, et al., Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res 2012; 52: 167-202.
15. Hardeland R,. Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms. J Pineal Res 2013; 55: 325-356.
16. Herrera EA, MacChiavello R, Montt C, et al., Melatonin improves cerebrovascular function and decreases oxidative stress in chronically hypoxic lambs. J Pineal Res 2014; 57: 33-42.
17. Reiter RJ, Tan DX, Kim SJ, et al., Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct Funct 2014; 219: 1873-1887.
18. Pevet P, Challet E,. Melatonin: both master clock output and internal time-giver in the circadian clocks network. J Physiol Paris 2011; 105: 170-182.
19. Calvo JR, Gonzalez-Yanes C, Maldonado MD,. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res 2013; 55: 103-120.
20. Romero A, Ramos E, De Los Rios C, et al., A review of metal-catalyzed molecular damage: protection by melatonin. J Pineal Res 2014; 56: 343-370.
21. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-257.
22. Zhang HM, Zhang Y,. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res 2014; 57: 131-146.
23. Lin L, Huang QX, Yang SS, et al., Melatonin in Alzheimer's disease. Int J Mol Sci 2013; 14: 14575-14593.
24. Cardinali DP, Furio AM, Brusco LI,. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr Neuropharmacol 2010; 8: 218-227.
25. Kolosova NG, Stefanova NA, Kolbolina EE, et al., The senescence-accelerated oxys rats-a genetic model of premature aging and age-dependent degenerative diseases. Adv Gerontol 2014; 27: 336-340.
26. Stefanova NA, Fursova AZ, Kolosova NG,. Behavioral effects induced by mitochondria-targeted antioxidant SkQ1 in Wistar and senescence-accelerated OXYS rats. J Alzheimers Dis 2010; 21: 479-491.
27. Stefanova NA, Fursova AZH, Sarsenbaev KN, et al., Effects of Cistanche deserticola on behavior and signs of cataract and retinopathy in senescence-accelerated OXYS rats. J Ethnopharmacol 2011; 138: 624-632.
28. Stefanova NA, Kozhevnikova OS, Vitovtov AO, et al., Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease. Cell Cycle 2014; 13: 898-909.
29. Stefanova NA, Muraleva NA, Skulachev VP, et al., Alzheimer's disease-like pathology in senescence-accelerated OXYS rats can be partially retarded with mitochondria-targeted antioxidant SkQ1. J Alzheimers Dis 2014; 38: 681-694.
30. Stefanova NA, Muraleva NA, Korbolina EE, et al., Amyloid accumulation is a late event in sporadic Alzheimer's disease-like pathology in nontransgenic rats. Oncotarget 2015; 6: 1396-1413.
31. Kolosova NG, Akulov AE, Stefanova NA, et al., Effect of malate on the development of rotenone-induced brain changes in Wistar and OXYS rats: an MRI study. Dokl Biol Sci 2011; 437: 72-75.
32. Rudnitskaya EA, Maksimova KY, Muraleva NA, et al., Beneficial effects of melatonin in a rat model of sporadic Alzheimer's disease. Biogerontology 2015; 16: 303-316.
33. Paxinos G, Watson CH,. The Rat Brain in Stereotaxic Coordinates, 6th edn. Elsevier, Academic Press, Sydney, Australia, 2007; pp. 456.
34. Brun A, Englund E,. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 1981; 5: 549-564.
35. Wright AL, Zinn R, Hohensinn B, et al., Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS ONE 2013; 8: e59586.
36. Harris KM, Weinberg RJ,. Ultrastructure of synapses in the mammalian brain. Cold Spring Harb Perspect Biol 2012; 4: doi: 10.1101/cshperspect.a005587
37. De Calignon A, Polydoro M, Suarez-Calvet M, et al., Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012; 73: 685-697.
38. Gylys KH, Fein JA, Yang F, et al., Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol 2004; 165: 1809-1817.
39. Scheff SW, Neltner JH, Nelson PT,. Is synaptic loss a unique hallmark of Alzheimer's disease? Biochem Pharmacol 2014; 88: 517-528.
40. Scheff SW, Price DA, Schmitt FA, et al., Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007; 68: 1501-1508.
41. Kamenetz F, Tomita T, Hsieh H, et al., APP processing and synaptic function. Neuron 2003; 37: 925-937.
42. Cirrito JR, Yamada KA, Finn MB, et al., Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005; 48: 913-922.
43. Gouras GK, Tampellini D, Takahashi RH, et al., Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 2010; 119: 523-541.
44. Crimins JL, Pooler A, Polydoro M, et al., The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev 2013; 12: 757-763.
45. Avila J,. Tau aggregation into fibrillar polymers: taupathies. FEBS Lett 2000; 476: 82-92.
46. Zhu X, Rottkamp CA, Boux H, et al., Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 880-888.
47. Gomez-Ramos A, Diaz-Nido J, Smith MA, et al., Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 2003; 71: 863-870. 42
48. Lovell MA, Xiong S, XIE C, et al., Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis 2004; 6: 659-671.
49. Krstic D, Madhusudan A, Doehner J, et al., Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 2012; 9: 151.
50. Kanaan NM, Morfini GA, Lapointe NE, et al., Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci 2011; 31: 9858-9868.
51. Shemesh OA, Erez H, Ginzburg I, et al., Tau-induced traffic jams reflect organelles accumulation at points of microtubule polar mismatching. Traffic 2008; 9: 458-471.
52. Shahpasand K, Uemura I, Saito T, et al., Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J Neurosci 2012; 32: 2430-2441.
53. Reiter RJ, Acuna-Castroviejo D, Tan DX, et al., Free radical-mediated molecular damage: mechanisms for the protective actions of melatonin in the central nervous system. Ann NY Acad Sci 2001; 939: 200-215.
54. Wang JZ, Wang ZF,. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 2006; 27: 41-49.
55. Schuster C, Williams LM, Morris A, et al., The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol 2005; 17: 170-178.
56. Peschke E, Muhlbauer E, Musshoff U, et al., Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res 2002; 33: 63-71.
57. Nguyen XKT, Lee J, Shin EJ, et al., Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCδ gene. J Pineal Res 2015; 58: 86-106.
58. Rivera-Bermudez MA, Gerdin MJ, Earnest DJ, et al., Regulation of basal rhythmicity in protein kinase C activity by melatonin in immortalized rat suprachiasmatic nucleus cells. Neurosci Lett 2003; 346: 37-40.
59. Tian Y, Yabuki Y, Moriguchi S, et al., Melatonin reverses the decreases in hippocampal protein serine/threonine kinases observed in an animal model of autism. J Pineal Res 2014; 56: 1-11.
60. Rimler A, Jockers R, Lupowitz Z, et al., Differential effects of melatonin and its downstream effector PKCalpha on subcellular localization of RGS proteins. J Pineal Res 2006; 40: 144-152.
61. Domínguez-Alonso A, Valdés-Tovar M, Solís-Chagoyán H, et al., Melatonin stimulates dendrite formation and complexity in the hilar zone of the rat hippocampus: participation of the Ca++/Calmodulin complex. Int J Mol Sci 2015; 16: 1907-1927.
62. Yin J, Liu YH, Xu YF, et al., Melatonin arrests peroxynitrite-induced tau hyperphosphorylation and the overactivation of protein kinases in rat brain. J Pineal Res 2006; 41: 124-129.
63. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al., Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003; 85: 1101-1108.
64. Quinn J, Kulhanek D, Nowlin J, et al., Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res 2005; 1037: 209-213.
65. Pappolla M, Bozner P, Soto C, et al., Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998; 273: 7185-7188.
66. Poeggeler B, Miravalle L, Zagorski MG, et al., Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry 2001; 40: 14995-15001.
67. Skribanek Z, Balaspiri L, Mak M,. Interaction between synthetic amyloid-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J Mass Spectrom 2001; 36: 1226-1229.
68. Shabalina IG, Kolosova NG, Grishanova AIU, et al., Oxidative phosphorylation activity, F0F1-ATPase and level of liver mitochondrial cytochromes in rats with congenitally increased ability for free radical formation. Biokhimiia 1995; 60: 2045-2052.
69. Kolosova NG, Aidagulova SV, Nepomnyashchikh GI, et al., Dynamics of structural and functional changes in hepatocyte mitochondria of senescence-accelerated OXYS rats. Bull Exp Biol Med 2001; 132: 814-819.
70. Markovets AM, Fursova AZ, Kolosova NG,. Therapeutic action of the mitochondria-targeted antioxidant SkQ1 on retinopathy in OXYS rats linked with improvement of VEGF and PEDF gene expression. PLoS ONE 2011; 6: e21682.
71. Vays VB, Eldarov CM, Vangely IM, et al., Antioxidant SkQ1 delays sarcopenia-associated damage of mitochondrial ultrastructure. Aging 2014; 6: 140-148.
72. Stefanova N, Zhdankina A, Fursova A, et al., Potential of melatonin for prevention of age-related macular degeneration: experimental study. Adv Gerontol 2013; 26: 122-129.
73. Ortiz GG, Sanchez-Ruiz MY, Tan DX, et al., Melatonin, vitamin E, and estrogen reduce damage induced by kainic acid in the hippocampus: potassium-stimulated GABA release. J Pineal Res 2001; 31: 62-67.
74. Sarlak G, Jenwitheesuk A, Chetsawang B, et al., Effects of melatonin on nervous system aging: neurogenesis and neurodegeneration. J Pharmacol Sci 2013; 123: 9-24.
75. Querfurth HW, Laferla FM,. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
76. Streit WJ, Braak H, Xue QS, et al., Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009; 118: 475-485.
77. Kassmann CM, Nave KA,. Oligodendroglial impact on axonal function and survival-a hypothesis. Curr Opin Neurol 2008; 21: 235-241.